SNCA and Parkinson disease: Ambroxol, historically used as an expectorant, has recently been trialled in patients withGBA1 mutation-associated PD, as it has been shown to facilitate the re-folding of glucocerebrosidase and increase its activity in human cells and transgenic mice with subsequent reduction in α-synuclein levels55,56.